The test, which was granted emergency use authorization in March, uses a nasal swab to detect RNA from the SARS-CoV-2 virus.
“False negative results may lead to delayed diagnosis or inappropriate treatment of SARS-CoV-2 that may cause patient harm, serious illness and death,” the FDA said.
False negatives could also lead to further spread of the virus, putting others at risk.
Quidel said it has received five complaints about the test, but no reports of injury or death.
Read the FDA’s full news release here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
